THERAVANCE BIOPHARMA INC (TBPH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TBPH - KYG8807B1068 - Common Stock

19.28 USD

+0.25 (+1.31%)

Last: 1/29/2026, 10:57:32 AM

Fundamental Rating

Overall TBPH gets a fundamental rating of 4 out of 10. We evaluated TBPH against 190 industry peers in the Pharmaceuticals industry. TBPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TBPH has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TBPH has reported negative net income.
In the past year TBPH had a positive cash flow from operations.
In the past 5 years TBPH reported 4 times negative net income.
In the past 5 years TBPH always reported negative operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of 7.06%, TBPH belongs to the best of the industry, outperforming 88.42% of the companies in the same industry.
TBPH's Return On Equity of 12.61% is amongst the best of the industry. TBPH outperforms 87.37% of its industry peers.

		Industry Rank	Sector Rank
ROA	7.06%
ROE	12.61%
ROIC	N/A

ROA(3y)37.73%

ROA(5y)0.15%

ROE(3y)46.45%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TBPH has a better Profit Margin (36.53%) than 96.84% of its industry peers.
TBPH does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	36.53%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
TBPH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TBPH has less shares outstanding
Compared to 1 year ago, TBPH has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 0.91, we must say that TBPH is in the distress zone and has some risk of bankruptcy.
TBPH has a Altman-Z score (0.91) which is in line with its industry peers.
TBPH has a debt to FCF ratio of 0.13. This is a very positive value and a sign of high solvency as it would only need 0.13 years to pay back of all of its debts.
TBPH's Debt to FCF ratio of 0.13 is amongst the best of the industry. TBPH outperforms 97.37% of its industry peers.
TBPH has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
TBPH has a Debt to Equity ratio (0.14) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.14
Debt/FCF	0.13
Altman-Z	0.91

ROIC/WACCN/A

WACC9.34%

2.3 Liquidity

TBPH has a Current Ratio of 9.48. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.48, TBPH is doing good in the industry, outperforming 78.95% of the companies in the same industry.
TBPH has a Quick Ratio of 9.48. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 9.48, TBPH is doing good in the industry, outperforming 78.95% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	9.48
Quick Ratio	9.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TBPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.53%.
Looking at the last year, TBPH shows a very strong growth in Revenue. The Revenue has grown by 27.12%.
The Revenue has been decreasing by -2.59% on average over the past years.

EPS 1Y (TTM)-10.53%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%126.92%

Revenue 1Y (TTM)27.12%

Revenue growth 3Y5.2%

Revenue growth 5Y-2.59%

Sales Q2Q%18.51%

3.2 Future

Based on estimates for the next years, TBPH will show a very strong growth in Earnings Per Share. The EPS will grow by 29.13% on average per year.
TBPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.36% yearly.

EPS Next Y277.35%

EPS Next 2Y69.83%

EPS Next 3Y24.98%

EPS Next 5Y29.13%

Revenue Next Year71.87%

Revenue Next 2Y26.75%

Revenue Next 3Y23.76%

Revenue Next 5Y31.36%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TBPH. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 20.00 indicates a rather expensive valuation of TBPH.
Based on the Price/Forward Earnings ratio, TBPH is valued a bit cheaper than the industry average as 77.37% of the companies are valued more expensively.
TBPH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.83, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	20

4.2 Price Multiples

98.42% of the companies in the same industry are more expensive than TBPH, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	4.01
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TBPH's earnings are expected to grow with 24.98% in the coming years.